Key Insights

Highlights

Treatment Research

2 treatments under study, led by Vrchivmab07500ab Vrc07523ls

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03565315Phase 1TerminatedPrimary

Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults

Showing all 1 trials

Research Network

Common Treatments

  • Vrchivmab07500ab Vrc07523ls1
  • Vrchivmab09500ab 10e8vls1

Active Sponsors

  • National Institute of Allergy and Infectious Diseases (NIAID)1

Top Investigators

Activity Timeline